Cutting Edge
The Rapid Evolution of Vaginal Mesh Delivery Systems for the Correction of Pelvic Organ Prolapse, Part I: Clinical Data
Littman PM, Culligan PJ
The Female Patient. 2009;34(4):32-38

Last fall, during a meeting of the ACOG Gynecologic Practice Committee, an FDA official was made aware of the current controversy surrounding vaginal mesh placement to correct pelvic organ prolapse. Three weeks later, on October 20th, the FDA issued a public health notification entitled “Serious Complications Associated with Transvaginal Placement of Surgical Mesh in Repair of Pelvic Organ Prolapse and Stress Urinary Incontinence.”1 This document made reference to “over 1,000 reports from nine surgical mesh manufacturers of complications associated with [vaginal] surgical mesh” and went on to list specific complications, such as mesh erosion through the vaginal epithelium, infection, pain, urinary problems, and prolapse recurrence.


Breaking News

More Headlines